REDUCED EXPANSION DOCUMENT FOR BME MTF EQUITY'S BME GROWTH TRADING SEGMENT

04 Apr 2025 20:03 CEST

FACEPHI BIOMETRÍA, S.A.

April 2025

This Reduced Expansion Document  has been drafted in accordance with the model established in Annex 2 of Circular 2/2020, of 30 July, on the requirements and procedure applicable to capital increases of entities whose shares are listed on the BME Growth segment of BME MTF Equity (hereinafter the "Market" or "BME Growth")) and has been prepared on the occasion of the listing on the Market of the newly issued securities subject to the capital increase.

Investors in companies traded in the BME Growth segment should be aware that they are taking on a greater risk than investing in companies listed on the Stock Exchange. Investment in companies traded in the BME Growth segment must be advised by an independent professional.

Shareholders and investors are advised to read this Reduced Expansion Document  in its entirety and carefully prior to any investment decision regarding the newly issued shares.

Neither the Governing Company of BME MTF Equity nor the Spanish National Securities Market Commission have approved or carried out any type of verification or verification in relation to the content of this Reduced Expansion Document  (the "Expansion Document " or "DAR"). The responsibility for the information published corresponds, at least, to the Issuing Entity and its administrators. The Market limits itself to checking that the information is complete, consistent and understandable.

darfacephicapital-increase-april-04-2025-vf.pdf